Ramón
García Sanz
Profesor Titular de Universidad
Hospital Virgen de la Concha
Zamora, EspañaPublicaciones en colaboración con investigadores/as de Hospital Virgen de la Concha (14)
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
2017
-
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
Haematologica, Vol. 102, Núm. 5, pp. 922-931
2016
-
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma
Leukemia, Vol. 30, Núm. 10, pp. 2026-2031
2015
-
The cellular origin and malignant transformation of Waldenström macroglobulinemia
Blood, Vol. 125, Núm. 15, pp. 2370-2380
2014
-
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma
Blood, Vol. 124, Núm. 8, pp. 1300-1303
-
Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification
Leukemia, Vol. 28, Núm. 1, pp. 166-173
2012
-
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Blood, Vol. 120, Núm. 13, pp. 2581-2588
2011
-
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Blood, Vol. 118, Núm. 17, pp. 4547-4553
-
The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis
Blood, Vol. 117, Núm. 13, pp. 3613-3616
2010
-
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial
The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941
-
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: Comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells
British Journal of Haematology, Vol. 148, Núm. 1, pp. 110-114
2007
-
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Blood, Vol. 110, Núm. 7, pp. 2586-2592
-
Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers
Cytotherapy, Vol. 9, Núm. 1, pp. 14-22
2004
-
Bone remodelation markers are useful in the management of monoclonal gammopathies
Hematology Journal, Vol. 5, Núm. 6, pp. 480-488